Geron Corporation (GERN)
NASDAQ: GERN · Real-Time Price · USD
1.310
+0.040 (3.15%)
At close: Dec 5, 2025, 4:00 PM EST
1.300
-0.010 (-0.76%)
After-hours: Dec 5, 2025, 7:24 PM EST
Geron Revenue
Geron had revenue of $47.23M in the quarter ending September 30, 2025, with 67.05% growth. This brings the company's revenue in the last twelve months to $183.40M, up 522.13% year-over-year. In the year 2024, Geron had annual revenue of $76.99M with 32,386.92% growth.
Revenue (ttm)
$183.40M
Revenue Growth
+522.13%
P/S Ratio
4.76
Revenue / Employee
$800,886
Employees
229
Market Cap
836.25M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 76.99M | 76.76M | 32,386.92% |
| Dec 31, 2023 | 237.00K | -359.00K | -60.23% |
| Dec 31, 2022 | 596.00K | -797.00K | -57.21% |
| Dec 31, 2021 | 1.39M | 1.14M | 450.59% |
| Dec 31, 2020 | 253.00K | -207.00K | -45.00% |
| Dec 31, 2019 | 460.00K | -606.00K | -56.85% |
| Dec 31, 2018 | 1.07M | 1,000.00 | 0.09% |
| Dec 31, 2017 | 1.07M | -5.10M | -82.72% |
| Dec 31, 2016 | 6.16M | -30.21M | -83.06% |
| Dec 31, 2015 | 36.37M | 35.22M | 3,054.47% |
| Dec 31, 2014 | 1.15M | -130.00K | -10.13% |
| Dec 31, 2013 | 1.28M | -1.43M | -52.64% |
| Dec 31, 2012 | 2.71M | 2.41M | 803.00% |
| Dec 31, 2011 | 300.00K | -625.00K | -67.57% |
| Dec 31, 2010 | 925.00K | 475.00K | 105.56% |
| Dec 31, 2009 | 450.00K | 156.00K | 53.06% |
| Dec 31, 2008 | 294.00K | -378.00K | -56.25% |
| Dec 31, 2007 | 672.00K | 50.00K | 8.04% |
| Dec 31, 2006 | 622.00K | 332.00K | 114.48% |
| Dec 31, 2005 | 290.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
GERN News
- 4 weeks ago - Geron: Rytelo Launch Stalls Out, EU Partnership And IMpactMF Results Could Help - Seeking Alpha
- 4 weeks ago - Geron Corporation (GERN) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Geron Corporation Reports Third Quarter 2025 Financial Results and Recent Business Highlights - Business Wire
- 4 weeks ago - Geron Corporation to Present at Upcoming Investor Conferences - Business Wire
- 4 weeks ago - Geron Corporation Announces Five Presentations Selected for ASH 2025 Highlighting Clinical Activity of RYTELO® (imetelstat) in Myeloid Hematologic Malignancies - Business Wire
- 5 weeks ago - Geron Plans to Announce Third Quarter 2025 Financial Results on November 5, 2025 - Business Wire
- 6 weeks ago - Geron Corporation: Early Momentum, Strong Leadership Plus Clear Path To Growth - Why I Buy - Seeking Alpha
- 6 weeks ago - Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire